MedPath

BioXcellerator

Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19

Phase 1
Terminated
Conditions
Acute Respiratory Distress Syndrome
Interventions
Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)
Drug: Wharton's jelly derived Mesenchymal stem cells.
First Posted Date
2020-05-15
Last Posted Date
2024-08-27
Lead Sponsor
BioXcellerator
Target Recruit Count
6
Registration Number
NCT04390152
Locations
🇨🇴

BioXcellerator, Medellin, Antioquia-CO, Colombia

🇨🇴

Clinical Somer, Rionegro, Antioquia, Colombia

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.